Breaking through convention to simplicity in T2DM care – Case study 3

shutterstock_2381590039 - Image for home page

Mitigate the risks of significant glycaemic variability in vulnerable insulin-treated T2DM patients with comorbidities; treatment intensification using iGlarLixi improves glucose control, offering long-term cardiorenal protection

Learning objectives

You will learn:

  • An understanding of the mechanism of action of GLP-1 agonists and how to use these agents
    safely and effectively
  • An understanding of the criteria that determine individualised HbA1c targets
  • An approach to the management of a patient with comorbid dyslipidaemia, hypertension, chronic kidney disease and ischaemic heart disease
  • The benefits of using fixed-dose combination insulin/GLP-1 agonist therapy to reduce other complications of type 2 diabetes mellitus (T2DM).

To access this module, please register or login: